Author:
Velasco Walter V.,Ramos-Castaneda Marco,Clowers Michael J.,Deng Shanshan,Moghaddam Seyed Javad
Reference129 articles.
1. Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents;Abraham;Journal of Clinical Oncology,2017
2. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers;Adjei;Journal of Clinical Oncology,2008
3. Efficacy of a covalent ERK1/2 inhibitor, CC-90003, in KRAS-mutant cancer models reveals novel mechanisms of response and resistance;Aronchik;Molecular Cancer Research,2019
4. Ras genes;Barbacid;Annual Review of Biochemistry,1987
5. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors;Bedard;Clinical Cancer Research,2015